Table 2 Clinical and treatment history for patients with viral load \(\ge\) 1000 copies/mL (N = 33).

From: High viral suppression and detection of dolutegravir-resistance associated mutations in treatment-experienced Tanzanian adults living with HIV-1 in Dar es Salaam

Participant ID

Age

Sex

Duration on ART years

Previous used regimen*

Duration on dolutegravir based regimen (months)

Reason for change to last regimen

CR-014

45

Female

10

1.TDF + FTC + EFV 2.TDF + 3TC + EFV 3.TDF + 3TC + DTG

48

PC

CR-048

25

Male

5

1.AZT + 3TC + NVP 2.TDF + 3TC + EFV 3.TDF + 3TC + DTG

48

PC

CR-063

47

Female

5

1.AZT + 3TC + NVP 2.AZT + 3TC + EFV 3.TDF + FTC + LPV/r 4.AZT + 3TC + LPV/r 5.ABC + 3TC + LPV/r

Not yet

RF

CR-119

38

Female

14

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG 3.ABC + 3TC + ATV/r

NA

RF

CR-177

40

Male

7

1.AZT + 3TC + NVP 2.TDF + 3TC + EFV 3.TDF + 3TC + DTG

48

PC

CR-226

36

Female

8

TDF + 3TC + DTG

48

PC

CR-335

45

Male

3

TDF + 3TC + DTG

35

PC

CR-339

72

Female

7

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

47

PC

CR-356

28

Female

2

TDF + 3TC + DTG

47

PC

FD-047

35

Female

8

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

46

PC

FD-089

38

Female

10

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

21

PC

FD-096

29

Female

5

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

21

PC

FD-143

36

Male

10

TDF + 3TC + DTG

16

PC

GD-103

60

Male

6

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

35

PC

GD-107

43

Female

11

TDF + 3TC + DTG

42

PC

MC-059

64

Male

6

1.AZT + 3TC + NVP 2.TDF + 3TC + EFV 3.TDF + 3TC + DTG

19

PC

MC-111

67

Male

10

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG 3.ABC + 3TC + DTG

23

PC

MC-118

35

Female

8

1. TDF + 3TC + EFV

2. TDF + 3TC + DTG

6

PC

MC-122

59

Female

11

TDF + 3TC + DTG

20

PC

MC-125

19

Male

3

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

27

PC

MC-210

48

Female

7

TDF + 3TC + DTG

24

PC

MC-222

52

Female

14

1.AZT + 3TC + NVP 2.TDF + 3TC + DTG 3.ABC + 3TC + DTG

38

PC

MC-243

51

Female

10

1.TDF + 3TC + EFV 2.ABC + 3TC + ATV/r 3.ABC + 3TC + DTG 4.TDF + 3TC + DTG

17

PC

MC-339

40

Female

2

1.AZT + 3TC + NVP 2.AZT + 3TC + EFV 3.TDF + 3TC + EFV 4.TDF + FTC + EFV 5.TDF + 3TC + DTG

38

PC

MC-347

18

Female

7

1.AZT + 3TC + NVP 2.TDF + 3TC + DTG

47

PC

MC-354

60

Female

11

1.AZT + 3TC + NVP 2.TDF + 3TC + EFV 3.TDF + 3TC + DTG

47

PC

MC-367

57

Female

10

1.AZT + 3TC + NVP 2.TDF + 3TC + DTG

48

PC

MC-400

40

Female

1

1.TDF + 3TC + DTG 2.ABC + 3TC + LPV/r

NA

RF

MU-050

39

Female

2

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

22

PC

MZ-030

38

Female

6

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

18

PC

MZ-113

37

Female

2

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

35

PC

MZ-207

50

Male

2

1.TDF + 3TC + EFV 2.TDF + 3TC + DTG

32

PC

MZ-262

27

Male

1

TDF + 3TC + DTG

15

PC

  1. 3TC lamivudine, ABC abacavir, AZT zidovudine, DTG dolutegravir, EFV efavirenz, FTC emtricitabine, NVP nevirapine, ATV/r atazanavir boosted by ritonavir, LPV/r lopinavir boosted by ritonavir, PC policy change (introduction of dolutegravir-based regimen as the first-line treatment in Tanzania), RF regimen failure, NA not available.
  2. *Regimen were used in a particular order (1, 2, 3, 4 and 5).
Back to article page